Antibody–Drug Conjugate, ADC:
2024 Market Insight, CDMO Pricing and Competitor Benchmarking
Over 500 cumulative hours of qualitative and quantitative data collection and analysis have been utilized to update Nice Insight’s Antibody–Drug Conjugate, ADC: 2024 Market Insight, CDMO Pricing and Competitor Benchmarking study.
Here are some facts about the 2024 report:
Research Started:
July 2024
Primary & Secondary Data Collection:
July 2024–August 2024
Collation & Analysis:
July 2024–August 2024
Development & Validation:
August 2024
Report Published:
September 2024
Revised December 2024
About This Report
In our first antibody–drug conjugate (ADC) report, we explore the manufacturing challenges, clinical trial landscape, and benchmark batch pricing for this new modality of therapeutics.
We have built a proprietary data analysis tool to analyze the state of clinical trials ongoing and completed in the U.S.
We evaluate trends in different payloads, trial size, and trial durations, along with top sponsors and top indications being studied.
We provide projections for ongoing growth of therapeutics entering the clinic and expecting approval, which will drive the need for manufacturing and analytical services.
We survey the regulatory, technical, and clinical challenges encountered by innovators and manufacturers in this burgeoning market.
We spoke with subject matter experts (SMEs) from contract development and manufacturing service providers and buyers of outsourced services.
We put the manufacturing market in context of ongoing geopolitical news.
Find Out Insights and Answers to These Questions
Innovators
Who are the major manufacturers in my target region?
Which CDMOs provide full end-to-end services, including development, manufacturing, formulation, and fill/finish?
How are other ADC developers managing the complex ADC value chain?
How much do we need to budget for a typical ADC manufacturing program?
How will IP concerns affect my ADC development program?
What companies are ahead of me in the clinical pipeline?
What conjugation techniques are easier to manufacture and why?
What titers can we expect, and therefore at what scale do we prepare RFPs?
Where are talent shortages most impacting CDMOs and what questions should I ask when evaluating a contractor?
What geopolitical news do I need to pay attention to?
Manufacturers
Who are my CDMO competitors in North America, Europe, and Asia?
What are the projected capacity expansions by my competitors, and where are they expanding?
How are other CDMOs attempting to simplify the ADC value chain for their clients?
How are competitors currently pricing their services?
What technology does my CDMO need to consider licensing or developing?
Who are the key innovators in the space, and how many projects are in their portfolios?
What new conjugation technologies should our firm prepare to manufacture?
What is the scale required for our potential clients?
How are other firms dealing with a shortage of talent and where might we find training programs?
How might geopolitics affect my firm?
What’s Included in This Report
First of its Kind Pricing Study
costs for key activities performed by CDMOs in this fast-growing industry
44 CDMO Profiles
including CDMOs with mammalian bioreactor capacity and associated activities
Analysis of Clinical Trial Landscape
to understand the current and future ADC modalities and manufacturing requirements
Market Growth Research
including projections for approved and late-stage ADCs
In-Depth Insight
from manufacturers and innovators on the IP, regulatory, technical, and financial landscape
Market Drivers
behind company expansions, layoffs, onshoring, and offshoring
Study Methodology
For the first edition of Nice Insight’s Antibody– Drug Conjugate, ADC: 2024 Market Insight, CDMO Pricing and Competitor Benchmarking study we have focused on the rapidly expanding ADC market. We updated all of our trends sections with up-to-date primary, proprietary data and a survey of secondary data from the published literature and industry databases to create a comprehensive outsourced development tool evaluating manufacturing of biologics in mammalian cells. The quantitative research that we performed is supplemented by direct interviews conducted with multiple SMEs with diverse roles in the sector to obtain qualitative perspectives on the dynamics of the space.
To build and analyze a dataset of ADC clinical trials, we created a proprietary search tool that uses the trials published at clinicaltrials.org since January 1, 2013. We probed the dataset in multiple queries to pull out all clinical trials, including building custom macros to mine the data based on drug name, modality, and keywords. We then carefully curated and cleaned the dataset for use in our analysis.
The data from 1,613 trials posted as of June 13, 2024 were curated to focus only on the investigation of ADC antibodies, separating them from classical monoclonal antibodies. This dataset was used to analyze innovators, funding, modalities, and more.
The content included here reflects in total over 1,000 hours of dedicated research, interviews, analysis, and composition, both to develop the 2024 pricing study and survey of clinical trials published.
A team comprising six Ph.D.-level experts collaborated with a group of 10+ SMEs within the ADC manufacturing and development sector to probe and better understand benchmarks, current challenges, and the future of the industry.
Our staff with over 80 years of industry experience worked for over four months to advise on big-picture trends shaping the industry and to unify the data into a holistic view.
Individual interviews were performed with SMEs representing leadership, manufacturing, innovators, and other operations at small and midsized CDMOs to discuss pricing for contract development and manufacturing services.